Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Summary

This phase II/III trial will investigate the ability of chemotherapy with 'Intensified Aklylating Agents (IAA) to achieve a high pathological complete response (pCR) rate when employed in the preoperative chemotherapy of breast cancer with evidence of a Homologous Recomination Deficiency (HRD).

Timeline

Start

2007-05

Primary completion

2010-02

Completion

2011-02

Drugs

Indications